The short version of Anti-doping fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-07. Anything still debated is marked as such rather than presented as settled.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
== Scholarly works == Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis, Published in Travel Medicine and Infectious Disease, Volume 34, March–April 2020 Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), Published in The Journal of Medical Virology, Volume 92 Issue 7, July 2020 Probable Zoonotic Leprosy in the Southern United States, Published in the New England Journal of Medicine, April 28, 2011. ChikDenMaZika Syndrome: the challenge of diagnosing arboviral infections in the midst of concurrent epidemics, Published in Annals of Clinical Microbiology and Antimicrobials, Article 42, July 22, 2016. Lobomycosis in Venezuela, Published in the International Journal of Dermatology, Volume 46, Issue 22, February 2007. Venezuela's humanitarian crisis, resurgence of vector-borne diseases, and implications for spillover in the region, Published in The Lancet, Volume 19, Issue 5, May 2019.
Aprepitant, sold under the brand name Emend among others, is a medication used to prevent chemotherapy-induced nausea and vomiting and to prevent postoperative nausea and vomiting. It may be used together with ondansetron and dexamethasone. It is taken by mouth or administered by intravenous injection. A prodrug, fosaprepitant, is also available for intravenous administration. Common side effects include tiredness, loss of appetite, diarrhea, abdominal pain, hiccups, itchiness, pneumonia, and blood pressure changes. Other severe side effects may include anaphylaxis. While use in pregnancy does not appear to be harmful, such use has not been well studied. Aprepitant belongs to the class of neurokinin-1 receptor antagonists. It works by blocking substance P from attaching to the NK1 receptors. Aprepitant was approved for medical use in the European Union and the United States in 2003. It is made by Merck & Co. It is on the World Health Organization's List of Essential Medicines.
Currently, only one vaccine (sipuleucel-T for prostate cancer) has been approved. In cell-mediated therapies like CAR-T cell therapy, immune cells are extracted from the patient, genetically engineered to recognize tumor-specific antigens, and returned to the patient. Cell types that can be used in this way are natural killer (NK) cells, lymphokine-activated killer cells, cytotoxic T cells, and dendritic cells. Finally, specific antibodies can be developed that recognize cancer cells and target them for destruction by the immune system. Examples of such antibodies include rituximab (targeting CD-20), trastuzumab (targeting HER-2), and cetuximab (targeting EGFR). Passive antibody therapies aim to increase the activity of the immune system without specifically targeting cancer cells. For example, cytokines directly stimulate the immune system and increase immune activity. Checkpoint inhibitors target proteins (immune checkpoints) that normally dampen the immune response. This enhances the ability of the immune system to attack cancer cells. Current research is identifying new potential targets to enhance immune function. Approved checkpoint inhibitors include antibodies such as ipilimumab, nivolumab, and pembrolizumab.
Sources: en.wikipedia.org
Abrams, J.L. Embalming. 2008. Chisholm, Hugh, ed. (1911). "Embalming" . Encyclopædia Britannica (11th ed.). Cambridge University Press. Frederick, L.G.; Strub, Clarence G. [1959] (1989). The Principles and Practice of Embalming, 5th ed., Dallas, TX: Professional Training Schools Inc & Robertine Frederick. OCLC 20723376. Mayer, Robert G. (2000). Embalming: History, Theory and Practice, 3rd ed., McGraw-Hill/Appleton & Lange. ISBN 978-0-8385-2187-8. Schmitz-Esser, Romedio (2013). "Embalming and Dissecting the Corpse between East and West: From ar-Razi to Henry de Mondeville". In Classen, Albrecht (ed.). East Meets West in the Middle Ages and Early Modern Times: Transcultural Experiences in the Premodern World. Fundamentals of Medieval and Early Modern Culture. Vol. 14. Berlin and Boston: De Gruyter. pp. 611–624. doi:10.1515/9783110321517.611. ISBN 9783110328783. ISSN 1864-3396. Besouchet, Lídia (1993). Pedro II e o Século XIX (in Portuguese) (2nd ed.). Rio de Janeiro: Nova Fronteira. ISBN 978-85-209-0494-7. Rezzutti, Paulo (2019). D. Pedro II: a história não contada: O último imperador do Novo Mundo revelado por cartas e documentos inéditos (in Portuguese). Leya. ISBN 978-85-7734-677-6. https://www.dignityfunerals.co.uk/what-to-do-when-someone-dies/what-is-embalming/
Globally, about 98 percent of soybean meal is used as animal feed. Of the US soybean production magnitude from 2010 through 2012, about 44 percent was exported as soybeans, and 53 percent was crushed in the US. Of the crushed tonnage, 19 percent was recovered as soybean oil and the remainder was recovered as soybean meal. Of the total US soybean tonnage produced, about 35 percent was fed to US livestock and poultry as soybean meal. Most of the remaining soybean meal produced in the US was exported. It has been estimated that, of soybean meal fed to animals in the US, 48 percent is fed to poultry, 26 percent to swine, 12 percent to beef cattle, 9 percent to dairy cattle, 3 percent is used in fish feed and about 2 percent in pet food. Although this implies that the tonnage of soybean meal fed to other species is relatively minor, such use is not unimportant. For example, for rapidly growing lambs on low-protein feeds, soybean meal can be an important supplement to ensure adequate protein intake, and partly because of its palatability, soybean meal is often recommended for use in starter rations when creep feeding lambs.
Provance, who ran a computer network used by military intelligence in the prison and who had been ordered not to speak to the press, told ABC News "Anything [the MPs] were to do legally or otherwise, they were to take those commands from the interrogators," and that the sexual humiliation began as a technique ordered by the investigators. He described several of the goings-on in the prison that he witnessed, such as the punching people in the neck hard enough to knock them unconscious after assuring them they weren't going to be hit, in order to catch them off guard. He also stated that Maj. Gen. George Fay, the Army's deputy chief of staff for intelligence, has shown little interest in investigating the interrogators and has gone only after the MPs, and that there is a culture of silence right now among those involved, who fear that if they say anything, the investigations will turn to them. On May 19, 2004, a court martial hearing was held for Cpl. Charles A. Graner Jr., who has been accused of being the ringleader of the group employing torture at Abu Ghraib. In an unexpected move, all three key witnesses - Lt. Col. Steven L. Jordan, Capt. Donald J. Reese, and contractor Adel L. Nakhla - refused to testify. This is an almost unheard of action. Under court martial proceedings, one cannot refuse to testify unless they have a belief that they will be exposed to criminal charges for doing so. Consequently, it is likely that the investigative proceedings will be forced to move higher up the chain of command.
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.